Nicox and Immco to develop Sjögren's syndrome diagnostic device

Article

Nicox has joined forces with Immco Diagnostics to offer tests for the early detection of Sjögren's syndrome.

Nicox has joined forces with Immco Diagnostics to offer tests for the early detection of Sjögren's syndrome.

The collaboration aims to give eye care practitioners and patients increased access to the test that offers potentially more efficient management of the chronic disease.

Undiagnosed Sjögren's syndrome could be discovered in as many as 1 in 10 dry eye patients and could lead to other disorders of the exocrine glands and an increased risk of lymphoma.

The new test, developed by researchers at the University at Buffalo, New York, USA, combines novel and traditional markers that support an accurate and early diagnosis with high sensitivity and specificity.

Nicox Inc Executive Vice President and General Manager, Mr Jerry St Peter, commented, “Immco is a well-established and innovative organization with a reputation for cutting edge science and high quality products. The addition of this new test into our portfolio synergizes well with our existing point-of-care offering, and will contribute to the momentum we are building in the marketplace with AdenoPlus.”

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.